bridgebio Reports the Results for Acoramidis in P-III Trial for the Treatmnet of Transthyretin Amyloid Cardiomyopathy
Shots:
- The P-III (ATTRibute-CM) clinical trial evaluates the safety & efficacy of Acoramidis (800mg, BID) vs PBO, in the ratio 2:1, in patients (n=632) with ATTR-CM for a duration of 30mos. The results were presented in the ‘New England Journal of Medicine’
- The 1EPs of the study include a 4-step hierarchical analysis incl. death, cardiovascular-related hospitalization, NT-proBNP level change, and 6min. walk distance change from baseline whereas the 2EPs include death from any cause, the 6min. walk distance, Kansas City Cardiomyopathy Questionnaire score & serum TTR level
- As per the pairwise comparisons, 62.7% vs 35.9% favoured Acoramidis over PBO, NT-proBNP yielded the highest ratio of wins to losses (23.3% vs. 7.0%) & the incidence of AEs were similar in both groups
Ref: BridgeBio | Image: BridgeBio
Related News:- BridgeBio Presents P-III Study (ATTRibute-CM) Results of Acoramidis for Transthyretin Amyloid Cardiomyopathy at ESC 2023
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
